Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR: Rosuvastatin vs Atorvastatin, Simvastatin, and Pravastatin in Hypercholesterolemia
NCT00654537Phase 3
Key facts
- Status
- Completed
- Start
- Apr 2001
- Sponsor
- AstraZeneca
- Modality
- Orthosteric Ligands
- Drugs
- rosuvastatin
- Conditions
- hypercholesterolemia
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in hypercholesterolemia (4 arms), sponsored by AstraZeneca. Primary endpoint: Percentage change in low density lipoprotein cholesterol at 6 weeks. Started Apr 2001; status: completed.
02
Design
4 arms- Study design
- RandomizedOpen-label
Rosuvastatin
Rosuvastatin 10, 20, 40, or 80 mg
Atorvastatin
Atorvastatin 10, 20, 40, or 80 mg
Pravastatin
Pravastatin 10, 20, or 40 mg
Simvastatin
Simvastatin 10, 20, 40, or 80 mg
03
Who it enrols
Adults with hypercholesterolemia (LDL-C 160-250 mg/dL) and triglycerides < 400 mg/dL, without active arterial disease.
04
Endpoints
Primary
Percentage change in low density lipoprotein cholesterol
Secondary
Percentage change in other lipid parameters
Safety evaluation
Beyond the preview
Go deeper on NCT00654537.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00654537.